ATA17892000A - Vakzin-zusammensetzung - Google Patents

Vakzin-zusammensetzung

Info

Publication number
ATA17892000A
ATA17892000A AT0178900A AT17892000A ATA17892000A AT A17892000 A ATA17892000 A AT A17892000A AT 0178900 A AT0178900 A AT 0178900A AT 17892000 A AT17892000 A AT 17892000A AT A17892000 A ATA17892000 A AT A17892000A
Authority
AT
Austria
Prior art keywords
peptide
amino acid
acid residue
group
antigen
Prior art date
Application number
AT0178900A
Other languages
English (en)
Other versions
AT410635B (de
Original Assignee
Cistem Biotechnologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AT0178900A priority Critical patent/AT410635B/de
Application filed by Cistem Biotechnologies Gmbh filed Critical Cistem Biotechnologies Gmbh
Priority to ES01980496T priority patent/ES2263668T3/es
Priority to MXPA03002828A priority patent/MXPA03002828A/es
Priority to EP01980496A priority patent/EP1326634B1/de
Priority to SK575-2003A priority patent/SK287618B6/sk
Priority to HU0302117A priority patent/HU228382B1/hu
Priority to AU1232602A priority patent/AU1232602A/xx
Priority to DE60119145T priority patent/DE60119145T2/de
Priority to CNB018171168A priority patent/CN1248736C/zh
Priority to JP2002535688A priority patent/JP4227407B2/ja
Priority to SI200130564T priority patent/SI1326634T1/sl
Priority to KR1020037004977A priority patent/KR100598302B1/ko
Priority to RU2003114434/15A priority patent/RU2328305C2/ru
Priority to DK01980496T priority patent/DK1326634T3/da
Priority to CZ20031299A priority patent/CZ303303B6/cs
Priority to PT01980496T priority patent/PT1326634E/pt
Priority to US10/399,442 priority patent/US8361476B2/en
Priority to AU2002212326A priority patent/AU2002212326B2/en
Priority to CA2426490A priority patent/CA2426490C/en
Priority to PCT/EP2001/012041 priority patent/WO2002032451A1/en
Priority to BR0114994-6 priority patent/BRPI0114994B8/pt
Priority to NZ524532A priority patent/NZ524532A/en
Priority to AT01980496T priority patent/ATE324116T1/de
Priority to HK03108189.1A priority patent/HK1055899B/en
Priority to PL362966A priority patent/PL209016B1/pl
Priority to IL15460501A priority patent/IL154605A0/xx
Publication of ATA17892000A publication Critical patent/ATA17892000A/de
Priority to IS6722A priority patent/IS2608B/is
Priority to ZA200301465A priority patent/ZA200301465B/en
Priority to IL154605A priority patent/IL154605A/en
Priority to NO20031595A priority patent/NO330274B1/no
Application granted granted Critical
Publication of AT410635B publication Critical patent/AT410635B/de
Priority to RU2007146372/15A priority patent/RU2007146372A/ru
Priority to US12/124,785 priority patent/US8900564B2/en
Priority to JP2008134215A priority patent/JP2008222721A/ja
Priority to US13/742,500 priority patent/US20130216583A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AT0178900A 2000-10-18 2000-10-18 Vakzin-zusammensetzung AT410635B (de)

Priority Applications (34)

Application Number Priority Date Filing Date Title
AT0178900A AT410635B (de) 2000-10-18 2000-10-18 Vakzin-zusammensetzung
MXPA03002828A MXPA03002828A (es) 2000-10-18 2001-10-18 Composicion de vacuna.
EP01980496A EP1326634B1 (de) 2000-10-18 2001-10-18 Ein antigen und ein adjuvans-peptid enthaltende impfstoffzusammensetzung
SK575-2003A SK287618B6 (sk) 2000-10-18 2001-10-18 Vakcína obsahujúca aspoň jeden antigén a peptid a použitie tohto peptidu
HU0302117A HU228382B1 (en) 2000-10-18 2001-10-18 Vaccine composition
AU1232602A AU1232602A (en) 2000-10-18 2001-10-18 Vaccine composition
DE60119145T DE60119145T2 (de) 2000-10-18 2001-10-18 Ein antigen und ein adjuvans-peptid enthaltende impfstoffzusammensetzung
CNB018171168A CN1248736C (zh) 2000-10-18 2001-10-18 疫苗组合物
JP2002535688A JP4227407B2 (ja) 2000-10-18 2001-10-18 ワクチン組成物
SI200130564T SI1326634T1 (sl) 2000-10-18 2001-10-18 Vakcinski sestavek, ki obsega antigen in peptid zadjuvantnimi lastnostmi
KR1020037004977A KR100598302B1 (ko) 2000-10-18 2001-10-18 백신 조성물
RU2003114434/15A RU2328305C2 (ru) 2000-10-18 2001-10-18 Вакцинная композиция
DK01980496T DK1326634T3 (da) 2000-10-18 2001-10-18 Vaccinepræparat der omfatter et antigen og et peptid med adjuvansegenskaber
CZ20031299A CZ303303B6 (cs) 2000-10-18 2001-10-18 Složená vakcína
PT01980496T PT1326634E (pt) 2000-10-18 2001-10-18 Composicao de vacina compreendendo um antigenio e um peptido possuindo propriedades adjuvantes
US10/399,442 US8361476B2 (en) 2000-10-18 2001-10-18 Vaccine composition comprising an antigen and a peptide having adjuvant properties
ES01980496T ES2263668T3 (es) 2000-10-18 2001-10-18 Composicion de vacuna que comprende un antigeno y un peptido con propiedades adyuvantes.
AU2002212326A AU2002212326B2 (en) 2000-10-18 2001-10-18 Vaccine composition comprising an antigen and a peptide having adjuvant properties
CA2426490A CA2426490C (en) 2000-10-18 2001-10-18 Vaccine composition comprising an antigen and a peptide having adjuvant properties
BR0114994-6 BRPI0114994B8 (pt) 2000-10-18 2001-10-18 composição de vacina
NZ524532A NZ524532A (en) 2000-10-18 2001-10-18 Vaccine composition
AT01980496T ATE324116T1 (de) 2000-10-18 2001-10-18 Ein antigen und ein adjuvans-peptid enthaltende impfstoffzusammensetzung
HK03108189.1A HK1055899B (en) 2000-10-18 2001-10-18 Vaccine composition comprising an antigen and a peptide having adjuvant properties
PL362966A PL209016B1 (pl) 2000-10-18 2001-10-18 Kompozycja szczepionek i zastosowanie polipeptydu do wytwarzania adiuwantu lub białka nośnikowego
IL15460501A IL154605A0 (en) 2000-10-18 2001-10-18 Vaccine composition
PCT/EP2001/012041 WO2002032451A1 (en) 2000-10-18 2001-10-18 Vaccine composition comprising an antigen and a peptide having adjuvant properties
IS6722A IS2608B (is) 2000-10-18 2003-02-20 Bóluefnissamsetning sem samanstendur af mótefnisvaka og peptíði sem hefur ónæmisglæðandi eiginleika.
IL154605A IL154605A (en) 2000-10-18 2003-02-24 A preparation that includes a peptide that is able to increase the immune response to the antigen given - jointly
ZA200301465A ZA200301465B (en) 2000-10-18 2003-02-24 Vaccine composition comprising an antigen and a peptide having adjuvant properties.
NO20031595A NO330274B1 (no) 2000-10-18 2003-04-08 Vaksine som omfatter minst ett antigen og et peptid med gitt sekvens, og anvendelse av peptidet til fremstilling av en adjuvans eller et baereprotein
RU2007146372/15A RU2007146372A (ru) 2000-10-18 2007-12-13 Вакцинная композиция
US12/124,785 US8900564B2 (en) 2000-10-18 2008-05-21 Vaccine composition comprising an antigen and a peptide having adjuvant properties
JP2008134215A JP2008222721A (ja) 2000-10-18 2008-05-22 ワクチン組成物
US13/742,500 US20130216583A1 (en) 2000-10-18 2013-01-16 Vaccine composition comprising an antigen and a peptide having adjuvant properties

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AT0178900A AT410635B (de) 2000-10-18 2000-10-18 Vakzin-zusammensetzung

Publications (2)

Publication Number Publication Date
ATA17892000A true ATA17892000A (de) 2002-11-15
AT410635B AT410635B (de) 2003-06-25

Family

ID=3688953

Family Applications (2)

Application Number Title Priority Date Filing Date
AT0178900A AT410635B (de) 2000-10-18 2000-10-18 Vakzin-zusammensetzung
AT01980496T ATE324116T1 (de) 2000-10-18 2001-10-18 Ein antigen und ein adjuvans-peptid enthaltende impfstoffzusammensetzung

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT01980496T ATE324116T1 (de) 2000-10-18 2001-10-18 Ein antigen und ein adjuvans-peptid enthaltende impfstoffzusammensetzung

Country Status (26)

Country Link
US (3) US8361476B2 (de)
EP (1) EP1326634B1 (de)
JP (2) JP4227407B2 (de)
KR (1) KR100598302B1 (de)
CN (1) CN1248736C (de)
AT (2) AT410635B (de)
AU (2) AU2002212326B2 (de)
BR (1) BRPI0114994B8 (de)
CA (1) CA2426490C (de)
CZ (1) CZ303303B6 (de)
DE (1) DE60119145T2 (de)
DK (1) DK1326634T3 (de)
ES (1) ES2263668T3 (de)
HU (1) HU228382B1 (de)
IL (2) IL154605A0 (de)
IS (1) IS2608B (de)
MX (1) MXPA03002828A (de)
NO (1) NO330274B1 (de)
NZ (1) NZ524532A (de)
PL (1) PL209016B1 (de)
PT (1) PT1326634E (de)
RU (2) RU2328305C2 (de)
SI (1) SI1326634T1 (de)
SK (1) SK287618B6 (de)
WO (1) WO2002032451A1 (de)
ZA (1) ZA200301465B (de)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT410635B (de) * 2000-10-18 2003-06-25 Cistem Biotechnologies Gmbh Vakzin-zusammensetzung
US7244438B2 (en) 2001-01-05 2007-07-17 Intercell Ag Uses for polycationic compounds
EP1347775B1 (de) * 2001-01-05 2016-11-30 Valneva Austria GmbH Gebrauch von polykationischen substanzen als adjuvantien für impfstoffe
AT410798B (de) 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
EP1279404A1 (de) 2001-07-26 2003-01-29 Istituto Superiore di Sanità Verwendung von HIV-1 Fragmenten oder Derivaten zur Bestimmung oder Aktivierung von Antigen-präsentierenden Zellen, oder zur Abgabe von Cargo-Molekülen für Impfung oder für Behandlung von anderen Erkrankungen
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
CA2484941A1 (en) 2002-07-24 2004-02-05 Intercell Ag Antigens encoded by alternative reading frame from pathogenic viruses
US7785608B2 (en) 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
EP1537418A2 (de) 2002-09-13 2005-06-08 Intercell AG Verfahren zur isolierung von hepatitis c virus peptiden
EP2314604A3 (de) 2002-10-15 2011-05-25 Intercell AG Bindungdsfaktoren von Gruppe B-Streptococcus, dafür kodierende Nukleinsäuren und Verwendungen davon
EP1601770B1 (de) 2003-03-04 2009-09-02 Intercell AG Streptococcus pyogenes antigene
EP2345420B1 (de) * 2003-03-24 2016-01-06 Valneva Austria GmbH Verwendung eines TH1-Immunantwort induzierenden Adjuvans zur Erhöhung der Immunantworten
CA2519922A1 (en) * 2003-03-24 2004-10-07 Intercell Ag Use of alum and a th1 immune response inducing adjuvant for enhancing immune responses
US7628994B2 (en) 2003-03-31 2009-12-08 Intercell Ag S. epidermidis antigens
CN1774447B (zh) 2003-04-15 2011-04-06 英特塞尔股份公司 肺炎链球菌抗原
US8076059B2 (en) 2003-04-16 2011-12-13 Duke University Adjuvant capable of specifically activating the adaptive immune response
AU2004235952A1 (en) 2003-05-07 2004-11-18 Intercell Ag Streptococcus agalactiae antigens I + II
EP2327720A1 (de) 2003-05-30 2011-06-01 Intercell AG Enterokokken-Antigene
EP2275131A3 (de) * 2003-07-11 2012-01-25 Intercell AG HCV-Impfstoff
EP1722819B1 (de) 2004-03-12 2007-12-26 Intercell AG Verfahren zur solubilisierung von peptid-mischungen
ES2556710T3 (es) 2004-09-24 2016-01-19 Novartis Ag Proteínas capsidiales VP1 modificadas del parvovirus B19
US20090269358A1 (en) 2005-10-07 2009-10-29 Shone Clifford C Proteins with Improved Solubility and Methods for Producing and Using Same
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
EP2040745B1 (de) 2006-06-28 2012-12-05 Statens Serum Institut Expansion des t-zell-repertoirs, um subdominante epitope durch impfung mit antigenen, die als proteinfragmente oder peptidcocktails abgegeben werden, aufzunehmen
EP2292648A3 (de) 2006-07-07 2011-06-08 Intercell AG Kleine Streptococcus-pyogenes-Antigene und Verwendung dafür
CN101516905A (zh) 2006-09-15 2009-08-26 英特塞尔股份公司 疏螺旋体属抗原
EP1923069A1 (de) 2006-11-20 2008-05-21 Intercell AG Schutzpeptide gegen S. pneumoniae und diesbezügliche Zusammensetzungen, Verfahren und Verwendungen
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
JP5437813B2 (ja) 2007-01-12 2014-03-12 インターセル アーゲー Ｓ．アガラクティエの防御タンパク質、その組み合わせ、およびそれを使用する方法
AU2008248755A1 (en) 2007-05-02 2008-11-13 Intercell Ag Klebsiella antigens
EP2012122A1 (de) 2007-07-06 2009-01-07 Medigene AG Strukturproteine von mutierten Parvoviren als Impfstoffe
US20100203083A1 (en) 2007-05-31 2010-08-12 Medigene Ag Mutated structural protein of a parvovirus
CN101883782A (zh) 2007-06-18 2010-11-10 英特塞尔股份公司 衣原体抗原
JP2011514167A (ja) 2008-03-17 2011-05-06 インターセル アーゲー 肺炎連鎖球菌（Ｓ．ｐｎｅｕｍｏｎｉａｅ）に対して保護的なペプチドならびにそれに関連する組成物、方法、および使用
WO2009123119A1 (ja) 2008-04-02 2009-10-08 国立大学法人徳島大学 合成ペプチドを含有する抗原薬物ビークルとこれを用いる粘膜ワクチン
CN102316894A (zh) 2008-06-20 2012-01-11 惠氏有限责任公司 来自β-溶血性链球菌菌株的ORF1358的组合物和使用方法
US20100015171A1 (en) * 2008-07-15 2010-01-21 Statens Serum Institute Vaccines comprising tb 10.4
EP2424882A2 (de) 2009-02-05 2012-03-07 Intercell AG Gegen e.-faecalis schützende peptide, verfahren und anwendungen, die damit in zusammenhang stehen
WO2010092176A2 (en) 2009-02-13 2010-08-19 Intercell Ag Nontypable haemophilus influenzae antigens
KR20140119165A (ko) 2009-06-22 2014-10-08 와이어쓰 엘엘씨 황색포도상구균 혈청형 5 및 8 협막 다당류 접합체 면역원성 조성물 및 이의 제조 방법
SG176837A1 (en) 2009-06-22 2012-01-30 Wyeth Llc Immunogenic compositions of staphylococcus aureus antigens
EP2470205A1 (de) 2009-08-27 2012-07-04 Novartis AG Hilfsstoff mit aluminium, oligonukleotid und polykation
EP2319871A1 (de) 2009-11-05 2011-05-11 Sanofi-aventis Polypeptide zum Binden an den Rezeptor für weiterentwickelte Glykierungsendprodukte sowie Zusammensetzungen und Verfahren, die diese Polypeptide beinhalten
PE20121689A1 (es) 2009-10-09 2012-12-14 Sanofi Sa Polipeptidos para union al receptor para productos finales de glicosilacion avanzada asi como composiciones y metodos que implican a los mismos
EP2308896A1 (de) 2009-10-09 2011-04-13 Sanofi-aventis Polypeptides zum Binden an den Rezeptor für weiterentwickelte Glykierungsendprodukte sowie Zusammensetzungen und Verfahren, die diese Polypeptide beinhalten
WO2011101465A1 (en) 2010-02-19 2011-08-25 Intercell Ag Ic31 nanoparticles
WO2012020326A1 (en) 2010-03-18 2012-02-16 Novartis Ag Adjuvanted vaccines for serogroup b meningococcus
PL3170508T3 (pl) 2010-06-04 2020-04-30 Wyeth Llc Preparaty szczepionek
ES2994878T3 (en) 2010-08-23 2025-02-03 Wyeth Llc Stable formulations of neisseria meningitidis rlp2086 antigens
ES2867375T3 (es) 2010-09-03 2021-10-20 Valneva Austria Gmbh Polipéptido aislado de las proteínas de la toxina A y la toxina B de C. difficile y sus usos
WO2012031760A1 (en) 2010-09-08 2012-03-15 Medigene Ag Parvovirus mutated structural proteins comprising cross - protective b - cell epitopes of a hpv l2 protein as well as products and methods relating thereto
KR101584871B1 (ko) 2010-09-10 2016-01-22 와이어쓰 엘엘씨 네이세리아 메닝기티디스 orf2086 항원의 비-지질화된 변이체
KR20130114210A (ko) 2010-12-22 2013-10-16 와이어쓰 엘엘씨 스타필로코커스 아우레우스 항원의 안정한 면역원성 조성물
BRPI1100857A2 (pt) * 2011-03-18 2013-05-21 Alexandre Eduardo Nowill agente imunomodulador e suas combinaÇÕes, seu uso e mÉtodo imunoterÁpico para a recontextualizaÇço, reprogramaÇço e reconduÇço do sistema imune em tempo real
ITMI20111182A1 (it) 2011-06-28 2012-12-29 Canio Buonavoglia Vaccino per coronavirus canino
BR122016004924A2 (pt) 2012-03-09 2019-07-30 Pfizer Inc. Polipeptídeo isolado e composições imunogênicas compreendendo os mesmos
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
AU2013259598B2 (en) * 2012-05-08 2018-10-04 Western University Of Health Sciences Standardized ex vivo platforms for the antigen-specific expansion of CD4+ T cell populations
JP6284537B2 (ja) * 2012-10-29 2018-02-28 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ アーカンソー 新規粘膜アジュバントおよびデリバリーシステム
PL2935299T3 (pl) 2012-12-20 2020-05-18 Pfizer Inc. Sposób glikokoniugacji
EP2964665B1 (de) 2013-03-08 2018-08-01 Pfizer Inc Immunogene fusionspolypeptide
US20140271723A1 (en) * 2013-03-15 2014-09-18 Saint Louis University Adjuvant compositions and methods of using thereof
CA2923129C (en) 2013-09-08 2020-06-09 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
WO2016130569A1 (en) 2015-02-09 2016-08-18 Mj Biologics, Inc. A composition comprising pedv antigens and methods for making and using the composition
WO2016132294A1 (en) 2015-02-19 2016-08-25 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
NZ736238A (en) 2015-05-04 2022-07-01 Pfizer Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof
CN113813231B (zh) * 2016-07-01 2022-06-21 四川大学 抗菌肽衍生物在制备核酸载体中的用途及核酸载体
US10751402B2 (en) 2016-11-09 2020-08-25 Pfizer Inc. Immunogenic compositions and uses thereof
US10183070B2 (en) 2017-01-31 2019-01-22 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
IL269830B2 (en) * 2017-04-04 2024-01-01 Avidea Tech Inc Peptide-based vaccines, methods of manufacturing, and uses thereof for inducing an immune response
CN107266585B (zh) * 2017-07-13 2019-08-06 陕西科技大学 一种mlh融合抗菌肽及其制备方法和应用
EP3527223A1 (de) 2018-02-16 2019-08-21 2A Pharma AB Mutiertes parvovirus-strukturprotein
CN112074295A (zh) 2018-02-16 2020-12-11 2A制药公司 用于治疗自身免疫性疾病的细小病毒结构蛋白
CN109745556A (zh) * 2019-03-01 2019-05-14 龙阔（苏州）生物工程有限公司 一种疫苗佐剂及其应用及猪繁殖与呼吸综合征疫苗
AU2020277661A1 (en) 2019-05-20 2021-10-21 Valneva Se A subunit vaccine for treatment or prevention of a respiratory tract infection
WO2021059181A1 (en) 2019-09-27 2021-04-01 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
US20230137756A1 (en) * 2020-03-30 2023-05-04 The Wistar Institute Of Anatomy And Biology Synthetic Soluble Receptor Mimics and Methods of Use for Treatment of COVID-19
EP4136095A1 (de) 2020-04-17 2023-02-22 Regents of the University of Minnesota Sars-cov-2-spike-rezeptorbindungsdomäne und zusammensetzungen und verfahren dafür
CA3192786A1 (en) 2020-08-26 2022-03-03 Pfizer Inc. Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof
WO2022214678A2 (en) 2021-04-09 2022-10-13 Valneva Se Human metapneumo virus vaccine
WO2023083964A1 (en) 2021-11-11 2023-05-19 2A Pharma Ab Parvovirus structural protein against beta- and gamma-hpv
CN120076825A (zh) 2022-09-29 2025-05-30 辉瑞公司 包含rsv f蛋白三聚体的免疫原组合物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ271774A (en) * 1993-08-06 1998-02-26 Cytel Corp Immunogenic peptides from the c-terminus of the mage-1 (melanoma) antigen
JP3442824B2 (ja) * 1993-08-30 2003-09-02 理化学研究所 抗菌性ペプチド類
JP3547504B2 (ja) * 1994-11-01 2004-07-28 独立行政法人理化学研究所 新規なポリペプチド及びその用途
CA2293826A1 (en) * 1997-06-11 1998-12-17 Brigitte Gicquel Attenuated recombinant mycobacteria useful as immunogens or as vaccine components
ES2248914T3 (es) * 1997-08-29 2006-03-16 Corixa Corporation Agentes bioactivos encapsulados de liberacion rapida que permiten inducir o potenciar una respuesta inmunitaria y metodos para utilizar los mismos.
CU22700A1 (es) * 1997-09-29 2001-07-31 Ct Ingenieria Genetica Biotech Formulación farmacéutica anti-viral que contiene un péptido de la proteína factor anti-lps de limulus y su uso
US20020072495A1 (en) * 2000-09-21 2002-06-13 Oleg Chertov LL-37 is an immunostimulant
AT410635B (de) * 2000-10-18 2003-06-25 Cistem Biotechnologies Gmbh Vakzin-zusammensetzung
CA2519922A1 (en) * 2003-03-24 2004-10-07 Intercell Ag Use of alum and a th1 immune response inducing adjuvant for enhancing immune responses
EP2345420B1 (de) 2003-03-24 2016-01-06 Valneva Austria GmbH Verwendung eines TH1-Immunantwort induzierenden Adjuvans zur Erhöhung der Immunantworten
EP2275131A3 (de) * 2003-07-11 2012-01-25 Intercell AG HCV-Impfstoff

Also Published As

Publication number Publication date
HK1055899A1 (en) 2004-01-30
RU2007146372A (ru) 2009-06-20
HU228382B1 (en) 2013-03-28
ES2263668T3 (es) 2006-12-16
NO20031595D0 (no) 2003-04-08
SK5752003A3 (en) 2003-12-02
BRPI0114994B1 (pt) 2017-11-07
CA2426490C (en) 2012-01-31
CZ20031299A3 (cs) 2003-10-15
AU1232602A (en) 2002-04-29
DE60119145D1 (de) 2006-06-01
CA2426490A1 (en) 2002-04-25
KR20030043993A (ko) 2003-06-02
BRPI0114994B8 (pt) 2021-05-25
JP4227407B2 (ja) 2009-02-18
JP2008222721A (ja) 2008-09-25
CN1468109A (zh) 2004-01-14
US8361476B2 (en) 2013-01-29
WO2002032451A1 (en) 2002-04-25
EP1326634B1 (de) 2006-04-26
US8900564B2 (en) 2014-12-02
NZ524532A (en) 2004-10-29
PT1326634E (pt) 2006-09-29
BR0114994A (pt) 2003-09-30
US20090123486A1 (en) 2009-05-14
NO330274B1 (no) 2011-03-14
IL154605A0 (en) 2003-09-17
SI1326634T1 (sl) 2006-10-31
AT410635B (de) 2003-06-25
AU2002212326B2 (en) 2006-01-05
EP1326634A1 (de) 2003-07-16
IS6722A (is) 2003-02-20
PL209016B1 (pl) 2011-07-29
CZ303303B6 (cs) 2012-07-25
PL362966A1 (en) 2004-11-02
NO20031595L (no) 2003-06-05
CN1248736C (zh) 2006-04-05
RU2328305C2 (ru) 2008-07-10
IS2608B (is) 2010-04-15
SK287618B6 (sk) 2011-04-05
JP2004511528A (ja) 2004-04-15
MXPA03002828A (es) 2003-07-14
ATE324116T1 (de) 2006-05-15
DE60119145T2 (de) 2007-02-01
IL154605A (en) 2009-05-04
HUP0302117A3 (en) 2004-11-29
HUP0302117A2 (hu) 2003-09-29
US20130216583A1 (en) 2013-08-22
ZA200301465B (en) 2004-02-24
WO2002032451A8 (en) 2002-05-23
US20050063978A1 (en) 2005-03-24
KR100598302B1 (ko) 2006-07-07
DK1326634T3 (da) 2006-08-14

Similar Documents

Publication Publication Date Title
IS6722A (is) Samsetning bóluefnis
ATE209216T1 (de) Cyclosporin-derivate mit anti-hiv-wirkung
RU2003114434A (ru) Вакцинная композиция
EP1548028A4 (de) Substituierte wt1-peptide
ATE557041T1 (de) Peptid-vakzinen gegen streptokokken der gruppe a
EA199900355A1 (ru) Теломераза обратная тринскриптаза
CY1108570T1 (el) Gd3-μιμητικα πεπτιδια
PT1290013E (pt) Derivados dos peptidos apo-ai/aii
ATE300619T1 (de) Humane checkpointkinase, hcds1, zusammensetzungen und verfahren
BR0309491A (pt) Composição de vacina, composição imunogênica, utilização de uma proteìna e7 e anticorpos neutralizantes
ATE474589T1 (de) Angiogene peptide und ihre verwendungen
WO2003097678A3 (en) Use of the repressor glxr for the synthesis of lysine in corynebacterium glutamicum
EA200100314A1 (ru) Пептидные фрагменты холерного экзотоксина в или энтеротоксина в в качестве адъювантов вакцины
MXPA02012664A (es) Peptidos para la preparacion de vacunas contra bordetella pertussis y bordetella parapertussis.
WO1994004565A3 (en) Ipnv vaccine
NZ508812A (en) Peptides for the prevention or treatment of HIV
DE69827880D1 (de) Iga1-protease fragment als trägerpeptid
DE60124299D1 (de) Peptide aus dem b-glycoprotein des menschlichen herpesvirus-7, besonders anwendbar bei serologischen elisa-nachweisen
WO2001074847A3 (en) T-cell epitope of mage-12 and related nucleic acids, vectors, cells, compositions and methods of inducing an immune response to cancer
EP0290246A3 (de) Impfstoff zur Erzeugung einer gegen Tollwutvirus schützenden immunogenen T-Zellen-Respons
SE0002738D0 (sv) Electric actuator

Legal Events

Date Code Title Description
PC Change of the owner

Owner name: INTERCELL AG, AT

Effective date: 20120919

PC Change of the owner

Owner name: VALNEVA AUSTRIA GMBH, AT

Effective date: 20140611

MK07 Expiry

Effective date: 20201018